<DOC>
	<DOC>NCT00358124</DOC>
	<brief_summary>To compare the glycemic control, as measured by HbA1C, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin</brief_summary>
	<brief_title>Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>INCLUSION CRITERIA: Diagnosis of type 2 diabetes mellitus for at least one year; Continuous treatment with at least half maximally labeled dose of a sulfonylurea and at least 1000 mg metformin daily for at least three months ; Glycated hemoglobin between 7.5 and 11 % units, inclusive; Willingness to accept, and ability to inject insulin glargine therapy EXCLUSION CRITERIA: Stroke, MI, coronary artery bypass graft, percutaneous transluminal coronary angioplasty or angina pectoris within the last 12 months; Congestive heart failure requiring pharmacological treatment; Serum creatinine &gt; 1.5 mg/dl for males, or &gt; 1.4 mg/dl for females; Acute or chronic metabolic acidosis, including diabetic ketoacidosis; Planned radiological examinations requiring administration of contrasting agents; Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range; History of hypoglycemia unawareness; Pregnancy or lactation; Failure to use adequate contraception (women of current reproductive potential only); Known hypersensitivity to insulin glargine, rosiglitazone or any of the components of insulin glargine rosiglitazone; BMI &gt;25 kg/m2; Malignancy except basal cell carcinoma within the last five years; History of substance or alcohol abuse within last two years, or current addiction to substance or alcohol abuse; Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study; Incapability to comply with study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>